2023
Adherence to Tumor Board Recommendations in the Treatment of Patients with Hepatocellular Carcinoma
Cao Y, Mezzacappa C, Jaffe A, Strazzabosco M, Taddei T. Adherence to Tumor Board Recommendations in the Treatment of Patients with Hepatocellular Carcinoma. Journal Of Multidisciplinary Healthcare 2023, 16: 1531-1540. PMID: 37283950, PMCID: PMC10239642, DOI: 10.2147/jmdh.s407908.Peer-Reviewed Original ResearchMultidisciplinary liver tumor boardBarcelona Clinic Liver CancerHepatocellular carcinomaBCLC stageLocoregional therapyTreatment-naïve hepatocellular carcinomaTreatment of HCCTumor board recommendationsRetrospective cohort studyTertiary care centerChronic liver diseaseMultivariate Cox regressionKaplan-Meier analysisManagement of patientsTreatment of patientsUnifocal hepatocellular carcinomaCases of discordanceBCLC guidelinesPalliative intentTreatment discordanceUnifocal diseaseChart reviewCohort studyCurative therapyCurative treatment
2010
Prediction of progression‐free survival in patients presenting with hepatocellular carcinoma within the Milan criteria
De Giorgio M, Vezzoli S, Cohen E, Armellini E, Lucà MG, Verga G, Pinelli D, Nani R, Valsecchi MG, Antolini L, Colledan M, Fagiuoli S, Strazzabosco M. Prediction of progression‐free survival in patients presenting with hepatocellular carcinoma within the Milan criteria. Liver Transplantation 2010, 16: 503-512. PMID: 20373461, DOI: 10.1002/lt.22039.Peer-Reviewed Original ResearchConceptsMilan criteriaProgression rateHepatocellular carcinomaRisk factorsObserved progression rateT2 patientsBarcelona Clinic Liver Cancer (BCLC) algorithmEnd-Stage Liver Disease exceptionOrgan allocationTumor persistence/recurrenceStage T2 patientsT2 hepatocellular carcinomaConsecutive HCC patientsProgression-free survivalChronic liver diseasePersistence/recurrenceDistinct natural historyTreatment of choiceBCLC guidelinesMELD scoreMELD exceptionsLocal therapyTransarterial chemoembolizationLiver diseaseTumor diameter